Impaired Hemorheology in Exacerbations of COPD

Table 2

Pulmonary function test results of the subjects.

Pulmonary function test	Control group; ( = 12)	Newly diagnosed patient group		Exacerbation group; ( = 16)
		Before treatment; ( = 13)	After treatment; ( = 13)
FVC (%)	97.67 ± 14.07	82.23 ± 13.97	88.77 ± 16.10	68.5 ± 30.6	0.005	0.006
FEV1 (%)	99.25 ± 12.83	66.69 ± 13.8	75.54 ± 20.1	64.36 ± 16.1	0.0001	0.0001
FEV1/FVC ratio	82.58 ± 6.04	63.85 ± 4.7	64.46 ± 8.6	60.93 ± 8.1	0.0001	0.0001
PEF (%)	90.33 ± 12.06	64.69 ± 16.1	70.54 ± 24.5	46.88 ± 29.3	0.0001	0.0001
FEF 25–75 (%)	90.67 ± 20.83	35.38 ± 9.4	42.08 ± 14.5	25.38 ± 16.2	0.0001	0.0001

Values are expressed as means ± SD (FEV₁: forced expiratory volume in the first second, FVC: forced vital capacity, PEF: peak expiratory flow, and FEF 25/75: forced expiratory flow 25% to 75%). : difference between the control group, before treatment of newly diagnosed COPD, and the exacerbation group; : difference between the control group, after treatment of newly diagnosed COPD, and the exacerbation group; < 0.05: difference from control, < 0.05: difference from before treatment of COPD, and < 0.05: difference from after treatment of COPD. and are findings via ANOVA whereas other symbols are findings by comparison of two groups.